ArticleCancer communications (London, England)2019
Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial.
Article in Cancer communications (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Trial
- Evolving Landscape of Glioblastoma Research: Integrating Therapeutic Advances and Diagnostic Frontiers.Brain sciences · 2026Review
- Comparative analysis of radiation therapy plans before and after biodegradable hydrogel (SpaceOAR) injection for reducing rectal toxicity in patients with prostate cancer undergoing carbon ion radiotherapy.Frontiers in oncology · 2026Article
- Impact of transducer arrays on deep-seated dosimetry in radiotherapy with concurrent TTFields for glioblastoma (extreme analysis).BMC cancer · 2025Article
- Review of Recent Improvements in Carbon Ion Radiation Therapy in the Treatment of Glioblastoma.Advances in radiation oncology · 2024Review
- CCNA2 and NEK2 regulate glioblastoma progression by targeting the cell cycle.Oncology letters · 2024Article
- Review
- Carbon-ion radiotherapy boost with standard dose proton radiation for incomplete-resected high-grade glioma: a phase 1 study.Annals of translational medicine · 2022Article
- Perfusion MR prior to radiotherapy is a strong predictor of survival in high-grade gliomas after proton and carbon ion radiotherapy.Annals of translational medicine · 2022Article
- Unraveling Mitochondrial Determinants of Tumor Response to Radiation Therapy.International journal of molecular sciences · 2022Review
- Flourish of Proton and Carbon Ion Radiotherapy in China.Frontiers in oncology · 2022Review
- Carbon ion radiotherapy boosts anti-tumour immune responses by inhibiting myeloid-derived suppressor cells in melanoma-bearing mice.Cell death discovery · 2021Article
- Role of Mitochondria in Radiation Responses: Epigenetic, Metabolic, and Signaling Impacts.International journal of molecular sciences · 2021Review
- Carbon-ion radiotherapy in osteosarcoma of the mandible: a case report.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2021Article
- The Emerging Potential of Multi-Ion Radiotherapy.Frontiers in oncology · 2021Article
- MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy.Frontiers in oncology · 2021Review
- Application of New Radiosensitizer Based on Nano-Biotechnology in the Treatment of Glioma.Frontiers in oncology · 2021Review
- Impact of Hypoxia on Carbon Ion Therapy in Glioblastoma Cells: Modulation by LET and Hypoxia-Dependent Genes.Cancers · 2020Article
- Different Mechanisms Underlie the Metabolic Response of GBM Stem-Like Cells to Ionizing Radiation: Biological and MRS Studies on Effects of Photons and Carbon Ions.International journal of molecular sciences · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma (GBM) is a highly virulent tumor of the central nervous system, with a median survival < 15 months. Clearly, an improvement in treatment outcomes is needed. However, the emergence of these malignancies within the delicate brain parenchyma and their infiltrative growth pattern severely limit the use of aggressive local therapies. The particle therapy represents a new promising therapeutic approach to circumvent these prohibitive conditions with improved treatment efficacy. METHODS AND
designPatients with newly diagnosed malignant gliomas will have their tumor tissue samples submitted for the analysis of the status of O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation. In Phase I, the patients will undergo an induction carbon ion radiotherapy (CIRT) boost followed by 60 GyE of proton irradiation with concurrent temozolomide (TMZ) at 75 mg/m DISCUSSION: The prognosis of GBM remains grim. The mechanism underpinning the poor prognosis of this malignancy is its chronic state of tumor hypoxia, which promotes both immunosuppression/immunologic evasion and radio-resistance. The unique physical and biological properties of CIRT are expected to overcome these microenvironmental limitations to confer an improved tumor-killing ability and anti-tumor immune response, which could result in an improvement in OS with minimal toxicity. Trial registration number This trial has been registered with the China Clinical Trials Registry, and was allocated the number ChiCTR-OID-17013702.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.